High Throughput Screening for Compounds That Alter Muscle Cell Glycosylation Identifies New Role for N-Glycans in Regulating Sarcolemmal Protein Abundance and Laminin Binding

Background: Genetic alteration of muscle cell glycosylation in muscular dystrophy models has ameliorated disease. Results: A high throughput screen identified a small molecule, lobeline, which altered muscle cell glycosylation and improved laminin binding. Conclusion: Lobeline increased abundance of sarcolemmal glycoproteins and increased laminin binding in an N-glycan-dependent manner. Significance: A novel approach revealed an unexpected role for N-glycans in muscle cell function. Duchenne muscular dystrophy is an X-linked disorder characterized by loss of dystrophin, a cytoskeletal protein that connects the actin cytoskeleton in skeletal muscle cells to extracellular matrix. Dystrophin binds to the cytoplasmic domain of the transmembrane glycoprotein β-dystroglycan (β-DG), which associates with cell surface α-dystroglycan (α-DG) that binds laminin in the extracellular matrix. β-DG can also associate with utrophin, and this differential association correlates with specific glycosylation changes on α-DG. Genetic modification of α-DG glycosylation can promote utrophin binding and rescue dystrophic phenotypes in mouse dystrophy models. We used high throughput screening with the plant lectin Wisteria floribunda agglutinin (WFA) to identify compounds that altered muscle cell surface glycosylation, with the goal of finding compounds that increase abundance of α-DG and associated sarcolemmal glycoproteins, increase utrophin usage, and increase laminin binding. We identified one compound, lobeline, from the Prestwick library of Food and Drug Administration-approved compounds that fulfilled these criteria, increasing WFA binding to C2C12 cells and to primary muscle cells from wild type and mdx mice. WFA binding and enhancement by lobeline required complex N-glycans but not O-mannose glycans that bind laminin. However, inhibiting complex N-glycan processing reduced laminin binding to muscle cell glycoproteins, although O-mannosylation was intact. Glycan analysis demonstrated a general increase in N-glycans on lobeline-treated cells rather than specific alterations in cell surface glycosylation, consistent with increased abundance of multiple sarcolemmal glycoproteins. This demonstrates the feasibility of high throughput screening with plant lectins to identify compounds that alter muscle cell glycosylation and identifies a novel role for N-glycans in regulating muscle cell function.

[1]  Peng Zhang,et al.  Differential glycosylation of α-dystroglycan and proteins other than α-dystroglycan by like-glycosyltransferase. , 2012, Glycobiology.

[2]  K. Campbell,et al.  Like-acetylglucosaminyltransferase (LARGE)-dependent modification of dystroglycan at Thr-317/319 is required for laminin binding and arenavirus infection , 2011, Proceedings of the National Academy of Sciences.

[3]  Peng Zhang,et al.  LARGE Expression Augments the Glycosylation of Glycoproteins in Addition to α-Dystroglycan Conferring Laminin Binding , 2011, PloS one.

[4]  L. Kunkel,et al.  Drug screening in a zebrafish model of Duchenne muscular dystrophy , 2011, Proceedings of the National Academy of Sciences.

[5]  Q. Lu,et al.  Large Induces Functional Glycans in an O-Mannosylation Dependent Manner and Targets GlcNAc Terminals on Alpha-Dystroglycan , 2011, PloS one.

[6]  J. Ervasti,et al.  Site Mapping and Characterization of O-Glycan Structures on α-Dystroglycan Isolated from Rabbit Skeletal Muscle* , 2010, The Journal of Biological Chemistry.

[7]  C. Eckman,et al.  Molecular Characterization of Mutations That Cause Globoid Cell Leukodystrophy and Pharmacological Rescue Using Small Molecule Chemical Chaperones , 2010, The Journal of Neuroscience.

[8]  Liping Yu,et al.  O-Mannosyl Phosphorylation of Alpha-Dystroglycan Is Required for Laminin Binding , 2010, Science.

[9]  P. Stanley,et al.  Mutational and functional analysis of Large in a novel CHO glycosylation mutant. , 2009, Glycobiology.

[10]  Rebekah L. Gundry,et al.  The Mouse C2C12 Myoblast Cell Surface N-Linked Glycoproteome , 2009, Molecular & Cellular Proteomics.

[11]  J. Hofsteenge,et al.  Deficiency of Dol-P-Man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the dystroglycanopathies. , 2009, American journal of human genetics.

[12]  J. Yoon,et al.  The synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: Partial dependence on utrophin , 2009, Molecular and Cellular Neuroscience.

[13]  M. Camboni,et al.  Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient mice. , 2009, The American journal of pathology.

[14]  Jae-Min Lim,et al.  IDAWG: Metabolic incorporation of stable isotope labels for quantitative glycomics of cultured cells. , 2009, Journal of proteome research.

[15]  A. Brancaccio,et al.  Functional diversity of dystroglycan. , 2009, Matrix biology : journal of the International Society for Matrix Biology.

[16]  S. Rhie,et al.  Myogenic Akt signaling upregulates the utrophin–glycoprotein complex and promotes sarcolemma stability in muscular dystrophy , 2008, Human molecular genetics.

[17]  S. Tapscott,et al.  Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy. , 2008, Human molecular genetics.

[18]  A. Janowsky,et al.  Lobeline effects on tonic and methamphetamine-induced dopamine release. , 2008, Biochemical pharmacology.

[19]  Alessio Ceroni,et al.  GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans. , 2008, Journal of proteome research.

[20]  J. Yoon,et al.  Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A. , 2007, The American journal of pathology.

[21]  K. Aoki,et al.  Dynamic Developmental Elaboration of N-Linked Glycan Complexity in the Drosophila melanogaster Embryo* , 2007, Journal of Biological Chemistry.

[22]  J. Ervasti Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. , 2007, Biochimica et biophysica acta.

[23]  D. Burkin,et al.  Severe muscular dystrophy in mice that lack dystrophin and α7 integrin , 2006, Journal of Cell Science.

[24]  A. Brancaccio,et al.  The dystroglycan complex: From biology to cancer , 2005, Journal of cellular physiology.

[25]  P. Stanley,et al.  Mouse Large Can Modify Complex N- and Mucin O-Glycans on α-Dystroglycan to Induce Laminin Binding* , 2005, Journal of Biological Chemistry.

[26]  V. Dubowitz,et al.  Lectin binding in human skeletal muscle: a comparison of 15 different lectins , 2005, The Histochemical Journal.

[27]  K. Campbell,et al.  LARGE can functionally bypass α-dystroglycan glycosylation defects in distinct congenital muscular dystrophies , 2004, Nature Medicine.

[28]  K. Campbell,et al.  Molecular Recognition by LARGE Is Essential for Expression of Functional Dystroglycan , 2004, Cell.

[29]  C. Esapa,et al.  The effects of post‐translational processing on dystroglycan synthesis and trafficking 1 , 2003, FEBS letters.

[30]  K. Campbell,et al.  Dystrophin-Glycoprotein Complex: Post-translational Processing and Dystroglycan Function* 210 , 2003, The Journal of Biological Chemistry.

[31]  K. Hoyte,et al.  Overexpression of the CT GalNAc transferase inhibits muscular dystrophy in a cleavage-resistant dystroglycan mutant mouse. , 2003, Biochemical and biophysical research communications.

[32]  K. Hoyte,et al.  Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  S. Dudoit,et al.  Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. , 2002, Nucleic acids research.

[34]  T. Deerinck,et al.  Overexpression of the CT GalNAc transferase in skeletal muscle alters myofiber growth, neuromuscular structure, and laminin expression. , 2002, Developmental biology.

[35]  L. Dwoskin,et al.  A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. , 2002, Biochemical pharmacology.

[36]  Terence P. Speed,et al.  Normalization for cDNA microarry data , 2001, SPIE BiOS.

[37]  B. Sperlágh,et al.  Multiple cellular mechanisms mediate the effect of lobeline on the release of norepinephrine. , 2000, The Journal of pharmacology and experimental therapeutics.

[38]  Nicolas Deconinck,et al.  Expression of full-length utrophin prevents muscular dystrophy in mdx mice , 1998, Nature Medicine.

[39]  K. Davies,et al.  The emerging family of dystrophin-related proteins. , 1994, Trends in cell biology.

[40]  J. Ervasti,et al.  Dystrophin-related protein is localized to neuromuscular junctions of adult skeletal muscle , 1991, Neuron.